



# Chiesi at a glance

Our performance in 2023



# *Sustainability* Report

**Chiesi Farmaceutici carefully assesses its environmental and societal sustainability performance each year.** Measuring and evaluating each operation is a fundamental aspect of the company commitment to **transparency and accountability** towards its stakeholders.

Progress in the crucial areas of work is regularly assessed, clearly identifying areas for improvement for Chiesi's four core areas: Patients, Planet, People and Prosperity.

The Sustainability Report provides a complete and precise summary of how Chiesi promotes **sustainable care**, together with patients, partners, suppliers and healthcare professionals who are an integral part of its system.



Frame the QR  
code to read  
the Sustainability  
Report 2023

# Chiesi Group *Overview*

A *global* company  
since 1935



**Benefit Corporation** in :  
**Italy** (*Società Benefit*)  
**United States**  
**France** (*Société à Mission*)



International  
biopharmaceutical Group,  
**B Corp certified**



**€ 3 billion** in sales

*Do Good, Do Well, Repeat*

At Chiesi, we believe in the principle of “**Do good, do well, repeat.**” This philosophy underscores our commitment to creating successful business solutions (“do well”) that benefit society (“do good”), and reinvesting in impactful initiatives (“repeat”). Our aim is to create a ripple effect of positive change, demonstrating that doing good and doing well are not only compatible but mutually reinforcing.

## Chiesi *in the world*



**4 Production plants** (Italy, France, Brazil and Germany) and **31 affiliates**. Our **therapeutic solutions** are distributed in more than **100** countries



**7 R&D centers:**  
Italy (Parma), Canada, China, France, United States, United Kingdom and Sweden

## *Research*-focused



**1<sup>st</sup>** among the Italian pharmaceutical companies and among the top 10 in Europe for R&D investments\*

Worldwide patents in  
Chiesi Group portfolio **6,201**



**43** patents applications in 2023  
**1<sup>st</sup>** among Italian pharmaceutical companies

\*European Commission - 2023 EU Industrial R&D Investment Scoreboard

## Our *workforce*

**7,122** employees *of which*  
**437** external collaborators

**6,685**  **56% female**

**Internal employees**  **44% male**

## Our *Business Areas*



Asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), bronchiectasis, pulmonary arterial hypertension (PAH), chronic cough  
**56% of sales**




Inborn errors of metabolism, rare hematologic and immunologic diseases, endo-metabolic disorders and dermatology  
**18% of sales**



Solid organ transplant, cardiovascular diseases, consumer healthcare / over the counter, neonatal RDS, primary apnoea of premature newborns **26% of sales**

# Prosperity

Our way of **doing business...**



...follows a global agenda...



...and is anchored in our bylaws.


## Benefit Corporation

Legal framework adopted in Italy, the U.S. and France

### GUIDING PRINCIPLES

## Economic Value Generated and Distributed

In 2023, over 77% of the economic value generated was distributed to stakeholders, with the remainder reinvested in the company



In 2023 we merged the Strategy and Sustainability departments to strengthen our sustainability governance, creating a brand new team

*Strategy, Sustainability and Growth Unit*

### HIGHLIGHTS

In 2023, we went a step further and created a strategy with ambitious goals to be better equipped for the future



### ROADMAP

# Patients



## Patient Journey

applied across our business areas



GUIDING PRINCIPLES

Gender Diversity  
in clinical trials

MEN 56.6% WOMEN 43.4%

## R&D Investments

€ 720.7M total expenses  
23.8% of sales reinvested internally

1,321 people of which 757 scientists  
Global R&D Staff

HIGHLIGHTS

Positive global impact through  
*Health Equity*  
efforts

Further develop our  
*Patient Journey framework*  
throughout the organization

ROADMAP

# Planet

## Do no harm



by protecting our planet and minimizing any negative impact produced by our activities

## Code of Interdependence



Supplier  
Code of Conduct  
co-created with  
our partners

## Climate Advocacy

Linking planetary and human health

### GUIDING PRINCIPLES

Transition to *renewable energy*

**99%** of total global electricity consumption from renewable sources



Carbon Disclosure  
Project 2023

Rating



EcoVadis

*Platinum Medal*

Score: 78/100

## The Economist *Impact report*


Cleaner Air, Clearer  
Lungs, Better  
Lives. Exploring  
the intersection of  
air quality, health  
inequalities and  
lung health



### HIGHLIGHTS

Reach Net Zero GHG emissions  
across the value chain

 **NET Zero**  
by **2035**



**€ 350 Million**

5-year investment in 2019 for  
development of low global  
warming potential propellant  
for pMDIs reducing their carbon  
footprint by up to *90%*

### ROADMAP

# People



## Human Leadership Model



### GUIDING PRINCIPLES

## Corporate Volunteering

More than  
**16,000**  
hours  
of volunteering  
**+77.5%** compared to 2022

**30.5%**  
Employee  
volunteer rate



## Professional Growth

More than  
**300,000**  
hours  
of training  
**+4%** compared to 2022

### HIGHLIGHTS



### ROADMAP

